Navigation Links
Epidemiology: Rheumatoid Arthritis in China - Rapid urbanization presents favorable market potential
Date:11/14/2012

NEW YORK, Nov. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epidemiology: Rheumatoid Arthritis in China – Rapid urbanization presents favorable market potential

http://www.reportlinker.com/p01037154/Epidemiology-Rheumatoid-Arthritis-in-China-–-Rapid-urbanization-presents-favorable-market-potential.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Datamonitor expects a substantial increase in prevalent rheumatoid arthritis in China over the next decade. In 2011, there were approximately 3.966 million total prevalent cases of rheumatoid arthritis (RA) in China. About 53% of RA cases were among people living in rural areas. However, by 2021, 57% of RA cases will be urban.Gain insight into market potential, including a robust 10-year epidemiology forecast of RA prevalence cases in China.Understand the key epidemiologic risk factors associated with RA in China.Ability to view granular RA data to more effectively target the highest burdened patient populations.

Datamonitor epidemiologists estimate that there were approximately 3.966 million total prevalent cases of rheumatoid arthritis in China in 2011.

Datamonitor expects to see a dramatic increase in total prevalent cases of rheumatoid arthritis in China over the next decade.

While an estimated 53% of RA cases were among people living in rural China in 2011, the number of total prevalent cases of RA in urban dwellers will increase to account for 57% of all RA cases by the end of 2021, which is a trend due to urbanization rates and rural-urban migration.

How many people are there with rheumatoid arthritis in China?How will the RA patient population change over the next decade in China?What proportion of RA patients are found in rural and urban areas, and in Tier 1 and Tier 2 cities?

OVERVIEW

•Catalyst•Summary

EXECUTIVE SUMMARY

•Disease background•Forecast results

DISEASE DEFINITION AND DIAGNOSTIC CRITERIA •Disease definition of rheumatoid arthritis

•Common diagnostic criteria for rheumatoid arthritis

GLOBAL VARIATION AND HISTORICAL TRENDS•Global variation•Contemporary trends - Incidence- Prevalence

•China

DRIVERS OF RHEUMATOID ARTHRITIS EPIDEMIOLOGY•Rheumatoid arthritis is a major cause of disability•Risk factors are largely unknown

EPIDEMIOLOGIC FORECASTING OF RHEUMATOID ARTHRITIS IN CHINA•Overview - Population denominators

•Description of methods - Sources of epidemiologic dataEPIDEMIOLOGIC RESULTS•Total prevalence of rheumatoid arthritis in China - National estimates- Rural/urban- Tier 1 cities- Tier 2 cities- Age and gender- Age-standardized prevalence ratesDISCUSSION•Strengths and limitations of Datamonitor's epidemiologic projections

BIBLIOGRAPHY

•Journal articles•Websites

TABLES

•Table: ACR/EULAR diagnostic criteria for rheumatoid arthritis •Table: Examples of co-morbid conditions associated with the occurrence of RA and their level and mechanism of relationship with RA•Table: Summary of sources used in this forecast•Table: Economic indicators in Chinese city tiers, 2005•Table: Total prevalent cases of rheumatoid arthritis in adults aged 25+ in China (000s), 2011–21•Table: Total prevalent cases of rheumatoid arthritis in China, by age group, 2011

FIGURES

•Figure: Percentage of population living in urban areas in China, 1950–2020•Figure: Total prevalent cases of rheumatoid arthritis in adults aged 25+ in China, by urban/rural (000s), 2011–21•Figure: Total prevalent cases of rheumatoid arthritis in major cities, China, 2011–21•Figure: Average annual growth rates of rheumatoid arthritis in China, by geographic area, 2011–21•Figure: Total prevalent cases of rheumatoid arthritis in China, by gender, 2011•Figure: Age-specific total prevalent cases of rheumatoid arthritis in China, 2011–21•Figure: Age-standardized total prevalence rates of rheumatoid arthritis in China, by gender, 2011

Companies Mentioned Aviva Plc, Fiskars Corporation, Hutchison 3G UK Limited, Schindler Holding Ltd.

To order this report:Pathology Industry: Epidemiology: Rheumatoid Arthritis in China – Rapid urbanization presents favorable market potential

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
2. Protalex, Inc. Announces Screening Of First Patients In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
5. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
6. TSI Healthcare adds Arthritis and Rheumatology Associates of Palm Beach to growing list of Rheumatology Clients
7. United States Market for Psoriatic Arthritis Pharmacotherapy
8. Arthritis Associates of South Florida Acquires Access to Patient Health History Faster with Digital Pen Technology from Anoto and NextGen Healthcare
9. Innovations for Osteoarthritis, Sports Injuries and Orthopedic Practices
10. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
11. China Nepstar Chain Drugstore to Report Third Quarter 2012 Financial Results on November 28, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... a Phase 2 clinical study of sotagliflozin, a dual ... with JDRF, the leading global organization funding type 1 ... 2 clinical trial, which randomized a total of 87 ... 400 mg dose of sotagliflozin compared to a placebo ...
(Date:12/5/2016)... -- Sharn Anesthesia Inc. announced today that it has been ... Salter Labs.  The company also received the 2015 Salter ... sales performance. Salter Labs is a leading ... the market gold standard ECO 2 sampling cannulas. ... Parker Flex-Tip® Endotracheal Tube, which is a leading patient ...
(Date:12/5/2016)... , the first HIPAA compliant software collaboration platform for patients, physicians ... Styku, a California -based software and ... real-time 3D body scanning and analysis. Together with its other strategic ... feel their health like never before. ... , , "Bringing ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson who has ... Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , The sessions ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... As renowned, ... heard the dangers and downsides of patients who do not do their research and ... of cosmetic dermatology is in the midst of a renaissance and every other month ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released study ... the reproducibility and accuracy of placing precordial electrodes with little cognitive effort and ... last 60 years, studies have shown that single electrode misplacement is one of ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
Breaking Medicine News(10 mins):